Trial ID | Phase / Target participants | Blinding | Intervention |
ChiCTR2000029569 | Phase 0 / 30 subjects | Open label | Experimental group: conventional treatment combined with umbilical cord mesenchymal stem cellconditioned medium group Control group: Conventional treatment |
NCT04339660 | Phase 1-2 / 30 Subjects | Triple-blinded | Experimental group: conventional and treatment with umbilical cord MSCs, 1x106 UC-MSCs /kg body weight suspended in 100mL saline Control group: conventional treatment and Placebo intravenously. Placebo 100mL saline intravenously |
NCT04336254 | Phase 1-2 / 20 Subjects | Triple-blinded | Experimental group: allogeneic human dental pulp stem cells Intravenous injection of 3.0x107 human dental pulp stem cells solution (30ml) on day 1, day 4 and day 7, based on routine treatment of COVID-19 Control group: Intravenous saline injection as Placebo Intravenous injection of 3ml of 0.9% saline on day 1, day 4 and day 7, based on routine treatment of COVID-19 |
NCT04288102 | Phase 2 / 90 Subjects | Quadruple-blinded | Experimental Group: Conventional treatment plus 3 times of MSCs(4.0x107 cells per time) intravenously at Day 0, Day 3, Day 6. Control Group: Saline containing 1% Human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6)Other: Intravenous saline injection (Placebo) Intravenous injection of 3ml of 0.9% saline on day 1, day 4 and day 7, based on routine treatment of COVID-19 |
ChiCTR2000030138 | Phase 2 / 60 subjects | Double Blinded | Experimental group: Intravenous injection of human umbilical cord mesenchymal stem cells (UC-MSC); Note: routine treatment combination was not mentioned in the other records. Control Group: Routine treatment + placebo |